Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

New Strong Sell Stocks for July 21st


Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:

Cadiz CDZI acquires and develops water-related land and agricultural assets. The Zacks Consensus Estimate for its current year earnings has been revised 40% downward over the last 60 days.

ArriVent BioPharma, Inc. AVBP is a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The Zacks Consensus Estimate for its current year earnings has been revised almost 7.3% downward over the last 60 days.

Acco Brands ACCO is a world leader in branded office products. The Zacks Consensus Estimate for its current year earnings has been revised 5.1% downward over the last 60 days.

View the entire Zacks Rank #5 List.

One Big Gain, Every Trading Day

To help you take full advantage of this market, you’re invited to access every stock recommendation in all our private portfolios - for just $1.

Zacks private portfolio services that closed 256 double and triple-digit winners in 2024 alone. That’s about one big gain every day the market was open. Of course, not all our picks are winners, but members have seen recent gains as high as +627% +1,340%, and +1,708%.

Imagine how much you could profit with a steady stream of real-time picks from all our services that cover a number of strategies to suit a variety of investing and trading styles.

See Stocks Now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Acco Brands Corporation (ACCO): Free Stock Analysis Report
 
Cadiz, Inc. (CDZI): Free Stock Analysis Report
 
ArriVent BioPharma, Inc. (AVBP): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research


Source Zacks-com

Like: 0
Share
At Zacks, we are dedicated to independent investment research, helping investors succeed through tools like our Zacks Rank stock-rating system, which has averaged +23.89% annual returns since 1988. Founded on the discovery that earnings estimate revisions drive stock prices, we offer purely mathematical, unbiased ratings, along with additional innovations like the Price Response Indicator, Earnings ESP, and specialized rankings for mutual funds and ETFs.
...
Legal notice

Comments